13th All-Ireland Conference of the Primary Care Diabetes Society | Diabetes on the Net

Diabetes on the Net is intended for healthcare professionals

Plotting a path to

high-quality care in diabetes

This year, the All-Ireland conference brings you the latest thinking and practical advice on diabetes in the primary care setting, and will be doing so in a new virtual format. Covering a broad range of topics, the speakers will highlight what new initiatives and changes mean for you in your everyday practice.The mix of lectures from leading healthcare professionals and interactive practical workshops will enable you – whatever your role in the primary care diabetes team – to come away having consolidated and built on your knowledge. You will also be able to work through the online CPD/CME templates throughout the day that you can take away to add to your personal development portfolio, all aimed at helping you put what you learn into practice.

We hope you will join us, virtually, for what is sure to be another invaluable event for your professional development.

Irish Representatives of the PCDS

Joanne Lowe, Community Diabetes Nurse Specialist, Co Wicklow
Lisa Devine, GP, Co. Wicklow

Why attend? This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more.

Ask the experts your burning questions through the LIVE Q&A at the end of each session

Log on anytime during the day from the comfort of your own home to view the sessions

Don’t worry if you miss something, all of the content will be available on-demand

Claim 5 CPD/CME points points for the full-day virtual conference

The agenda

is still being confirmed for this conference,
please check back for updates.

21 November 2020


09.00 - 09.10

Chair’s introduction

Joanne Lowe

09.10 - 09.40

What has COVID-19 taught us?

- Lessons for diabetes care
- What we can expect in the coming months

15 minute break

09.55 - 10.25


15 minute break

10.40 - 11.10

New ways of working post-COVID-19 – performing remote reviews

- The impact of COVID-19 on the provision of routine diabetes reviews in primary care
- Delivering reviews in a way that minimises face-to-face contact – the priorities, processes and practicalities of remote working
- What works well and what improvements can we make?

15 minute break

11.25 - 12.05

‘In Practice’ masterclasses

Rotation 1

1. Injectables

2. Discover diabetes

3. Podiatry

4. ‘In association’ masterclass

15 minute break

12.20 - 13.00

Rotation 2

1. Injectables

2. Discover diabetes

3. Podiatry

15 minute break

13.15 - 13.45

Vulnerable groups in diabetes

- What we can do to improve access to care for vulnerable groups
- Interview style Q&A session

15 minute break

14.00 - 14.30


15 minute break

14.45 - 15.15

Diabetes distilled Emerging evidence from the weeks and months before the conference

15.15 - 15.25

Chair’s concluding remarks

Joanne Lowe

A full-day virtual conference

21 November 2020 from 9am

Including a LIVE Q&A after every session


Heather Bell, GP


Nigel Campbell

GP, Lisburn

Hamish Courtney

Consultant Diabetologist, Belfast

Mark Davies

Consultant Clinical Psychologist, Belfast

Su Down

Diabetes Nurse Consultant, Somerset

Kevin Fernando

GPwSI in Diabetes and Medical Education, North Berwick

Lesley Hamilton

Diabetes Network Manager, Western Trust

Rose Stewart

Principal Clinical Psychologist




AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

AstraZeneca has five different sites in the UK, where approximately 6,500 employees work in research and development, manufacturing, supply, sales and marketing. We supply over 40 different medicines to the NHS, helping to treat approximately one million patients with serious diseases. The UK is also an important location for AstraZeneca’s clinical trials; in 2017 there were 191 AZ and Medimmune clinical trials at 340 sites in the UK, involving 8,747 patients. For more information, please visit www.astrazeneca.co.uk.

Eli Lilly and Company Ltd

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.co.uk


Napp Pharmaceuticals Limited

Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. We strive to offer new medicines and initiatives that support the NHS in delivering effective, high-quality, sustainable healthcare for the benefit of patients

Masterclass sponsor

Abbott’s Diabetes Care Division

Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk


Boehringer Ingelheim and Lilly Diabetes Alliance

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care.  This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: diabetes, haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. Every day, millions of people all over the world rely on our products, which are manufactured in nine countries.
Novo Nordisk has a unique ownership structure, with two-thirds of Novo Nordisk’s shares controlled by the Novo Nordisk Foundation. The objective of the Foundation is to provide a stable basis for the commercial and research activities of Novo Nordisk and support scientific, humanitarian and social purposes.
As the acknowledged leader in diabetes care, we work to prevent, treat and ultimately cure this increasingly onerous disease. Over the past 90 years, our researchers have pioneered many breakthroughs in its management, and today, our determination to help these people is stronger than ever.
Novo Nordisk also holds leading positions in the management of bleeding disorders, growth hormone treatment and hormone replacement therapy. We are currently researching into novel delivery systems and autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies.


This conference was developed by the PCDS in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the conference agenda, speaker selection or presentations, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

21 November 2020

Complete the registration form

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.

21 November 2020


Thanks for registering